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Abstract In a recent study, we have shown that in mammary
tumors from mice lacking the Cav-1 gene, there are alterations
in specific heat shock proteins as well as in tumor development.
With this in mind, we have now investigated other proteins in
the same mammary mouse tumor model (Her-2/neu expressing
mammary tumors from Cav-1 wild type and Cav-1 null mice),
to further comprehend the complex tumor-stroma mechanisms
involved in regulating stress responses during tumor develop-
ment. In this tumor model the cancer cells always lacked of
Cav-1, so the KO influenced the Cav-1 in the stroma. By
immunohistochemistry, we have found a striking co-
expression of β-catenin and Her-2/neu in the tumor cells.
The absence of Cav-1 in the tumor stroma had no effect on
expression or localization of β-catenin and Her-2/neu. Both
proteins appeared co-localized at the cell surface during tumor
development and progression. Since Her-2/neu activation
induces MTA1, we next evaluated MTA1 in the mouse
tumors. Although this protein was found in numerous nuclei,
the absence of Cav-1 did not alter its expression level. In
contrast, significantly more PTEN protein was noted in the
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tumors lacking Cav-1 in the stroma, with the protein localized
mainly in the nuclei. P-Akt levels were relatively low in
tumors from both Cav-1 WT and Cav-1 KO mice. There
was also an increase in nuclear NHERF1 expression levels
in the tumors arising from Cav-1 KO mice. The data obtained
in the MMTV-neu model are consistent with a role for Cav-1
in adjacent breast cancer stromal cells in modulating the
expression and localization of important proteins implicated
in tumor cell behavior.
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Abbreviation
Cav-1 Caveolin-1
EMT Epithelial to mesenchymal transition
ER Estrogen receptor
Her-2/neu c-erbB-2
HSP Heat shock protein
IHC Immunohistochemistry
KO Knockout
MMTV Murine mammary tumor virus
MTA1 Metastasis associated protein 1
NHERF1 Na+/H+ exchanger regulator factor 1
PR Progesterone receptor
PTEN Phosphatase and tensin homologue
deleted on chromosome 10
WT Wild type
Introduction
In a previous study of human breast cancer samples, we
reported that high levels of Cav-1 in stromal tissues surround-
ing the tumor were strongly associated with reduced metastasis
and improved survival (Sloan et al. 2009). In this study, we
also report (in a MMTV-c-neu transgenic mouse tumor model)
that the onset of mammary tumors driven by specific expres-
sion of Her-2/neu is accelerated in mice lacking Cav-1−/−,
supporting the concept that the presence of Cav-1 in the tumor
microenvironment regulates the rate of tumor development.
We then hypothesize that since the loss of Cav-1 has been
related to oxidative stress (Pavlides et al. 2010) and that the
heat shock proteins (HSPs) are induced by stress (Kampinga et
al. 2009), the absence of Cav-1 is likely to initiate a stress
response in the tumor cells. In fact, this was reported in a recent
study where the levels of Hsp70 (HSPA)were almost double in
Cav-1−/− tumors compared to Cav-1+/+ tumors (Ciocca et al.
2012). In contrast, Hsp27/Hsp25 (HSPB1) levels were signif-
icantly lower in the Cav-1−/− tumors. Moreover, in mammary
tumors from animals lacking Cav-1, we found a significant
reduction in the extent of apoptosis, demonstrating that the
disruption of the Cav-1 gene can cause alterations in specific
HSPs as well as in tumor cell survival.
In the present study, using this unique tumor model (Her-
2/neu expressing mammary tumors from Cav-1 wild type
and Cav-1 null mice), we examined other proteins with the
aim of advancing our understanding of the complexity of
regulation of stress response and tumor development. We
selected a series of proteins that are all mechanistically
related with stress and/or heat shock protein response:
β-catenin, MTA1, PTEN, Akt and NHERF1.
In human breast cancer cells and tissues, β-catenin inter-
acts with Hsp27, Cav-1, and heat shock factor 1, interactions
that may explain some of the molecular pathways that influ-
ence tumor cell survival and disease outcome (Fanelli et al.
2008). In addition, it has been shown previously that the
simultaneous deregulation of both: (a) Wnt signaling through
β-catenin and (b) Her-2/neu, cooperate to induce mammary
gland tumors in transgenic mice (Schroeder et al. 2002).
MTA1 was selected because in human breast cancer,
heregulin, which is an indirect activator of the Her-2/neu
pathway, strongly induced MTA1/heat shock factor 1 com-
plexes with a number of associated proteins, including his-
tone deacetylases HDAC1, HDAC2 and Mi2, that are
components of the NuRD co-repressor complex (Khaleque
et al. 2008). These complexes participate in the repression of
estrogen-dependent transcription and can explain, at least in
part, the shorter disease-free survival and overall survival
reported in breast cancer patients whose tumors co-express
ERs and/or PRs with Her-2/neu (Ciocca et al. 2006).
PTEN is a tumor suppressor gene encoding an enzyme
involved in the regulation of various cellular processes. The
tumor suppressor function may be explained by its activity as a
protein tyrosine phosphatase and as a phosphatidylinositol
phosphate (PIP) phosphatase (Moncalero et al. 2011). The
PI3K/Akt signaling pathway is negatively regulated by
PTEN. Mutations, deletions or silencing of PTEN cause
increases in the PI3K signal, which in turn stimulate down-
stream Akt signaling leading to promotion of growth factor-
independent growth and increased cell invasion and metastasis
(Hafsi et al. 2012). Activated Akt is a well-established survival
factor, exerting anti-apoptotic activity by preventing the release
of cytochrome C from mitochondria and inactivating Forkhead
transcription factors (FKHR), which are known to induce the
expression of genes that are critical for apoptosis (Fukunaga
and Shioda 2009; Fiandalo and Kyprianou 2012). We have
recent evidence to indicate that the down-regulation of Hsp27
(HSPB1) in MCF-7 human breast cancer cells induces up-
regulation of PTEN and reduces p-Akt levels (Cayado-
Gutiérrez et al. 2012).
Finally, we also analyzed the adaptor protein NHERF1,
because of its important role in maintaining the integrity of
cell–cell interactions and in stabilizing E-cadherin/β-catenin
complexes (Kreimann et al. 2007). NHERF1 may act as a
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tumor suppressor gene or as an oncogene depending on the
cell type and its subcellular localization (Shibata et al. 2003;
Pan et al. 2006). The molecular interaction of NHERF1 and
PTEN has been described previously (Molina et al. 2012),
and NHERF1 is required for 17-β-estradiol-increased PTEN
expression (Yang et al. 2011).
Materials and methods
Tumor bearing mice
Mice lacking Cav-1 and with mammary-specific expression
of Her-2/neu were generated by crossing Cav-1 null mice
(129/Sv/C57Bl/6) obtained from Dr. T. Kurzchalia (Drab et
al. 2001) to mice transgenic for the MMTV-neu oncogene
(Guy et al. 1992) as described previously (Sloan et al. 2009).
Once the mammary tumors became palpable they were
measured weekly using electronic callipers and mice were
culled when the primary tumor reached a volume of
1,500 mm3. The tumors were removed at autopsy, weighed
and fixed in 10 % buffered formalin, dehydrated and embed-
ded in paraffin. A total of 15 animals were examined, the
tumors were removed from eight mice with Cav-1+/+ and from
seven mice with Cav-1−/−. All procedures were performed in a
barrier facility under protocols approved by the Peter
MacCallum Animal Experimentation Ethics Committee.
Immunohistochemistry (IHC)
Hematoxylin and eosin-stained tissue sections (5μm thickness)
were used for histopathological studies. Serial 5-μm-thick sec-
tions were mounted onto 3-aminopropyltriethoxysilane-coated
slides (Sigma-Aldrich, St. Louis, MO) for subsequent IHC
analysis, which was performed in duplicate (two sections per
tumor for each antibody). The primary antibodies used in this
study are described in Table 1. An antigen retrieval protocol
using heat was used to unmask the antigens (30 min in citrate
buffer 0.01M, pH6.0). Tissue sections were incubated with the
primary antibodies overnight at 4 °C in humidity chambers at
the dilutions given in Table 1. A commercial kit to detect
mouse and rabbit primary antibodies was used (Dako
EnVision system, horseradish peroxidase, diaminobenzidine
[DAB]; Dako, Carpinteria, CA). Slides were lightly counter-
stained with hematoxylin to reveal nuclei, examined and photo-
graphed with a Nikon Eclipse E200 microscope (Japan). Non-
specific mouse IgG1 antibody and purified rabbit pre-immune
serum (Dako, Kingsgrove, NSW, Australia) were used as iso-
type negative controls. As positive controls we used breast
cancer tissue blocks from our tumor bank (Sloan et al. 2009),
and the skin tissue of the mice, the optimal dilution of each
antibody was tested using these samples. The immunostaining
was evaluated in the whole sections with the extent and inten-
sity of immunostaining assessed independently by two experi-
enced researchers blinded to the Cav-1 status of the sample.
Disagreements (<10 %, often relating to the level of staining
intensity) were resolved by consensus. We used a scoring
system reported previously (Gago et al. 1998). Briefly, we used
an intensity score: 0 = no staining, 1 = weak staining, 2 =
moderate staining, 3 = strong staining and a proportion
score: 0 = no staining, 1 = staining in less than 1/10 of the cells,
2=1/10 to <1/3 of the cells, 3=1/3 to <2/3 of the cells, and
4=>2/3 of the cells. The total was obtained by combining
both intensity and proportion scores, which were reported
for membrane, cytoplasmic and nuclear cell compartments.
The lack of frozen tissues prevents us from complementing
the IHC analysis with more quantitative methods like
Western blotting.
Cells and Western blots
Human MCF-7 breast cancer cells were used to test the
specificity of the antibodies used in the present study.
Description of the cell growing conditions and the Western
blot technique have been presented elsewhere (Cayado-
Gutiérrez et al. 2012).
Table 1 Main characteristics of the antibodies used in the present study
Antibody Source Dilution
Her-2/neu rPAb (Dako, Glostrup, Denmark) 1:200
β-Catenin mMAb (Cat 5H10, Zymed, San Francisco, CA) 1:400
MTA1 rPAb (affinity purified, BL1803; Bethyl, Montgomery, TX) 1:100
PTENa rPAb (generated against a PTEN synthetic peptide sequence between
amino acids 33 to 47 (Perandones et al. 2004)
1:100
PTENb rPAb (raised against a peptide mapping at the C terminus of PTEN
of human origin PTEN C-20 sc-6817-R; Santa Cruz Biotech., Santa Cruz, CA)
1:200
p-Akt rPAb (generated against an epitope corresponding to amino acids 345–480
of Akt1 of human origin. This antibody detects Akt1, Akt2 and Akt3 (H-136, sc-8312, Santa Cruz).
1:1,000
NHERF1 rPAb (PA 1–090, Affinity BioReagents, Rochford, IL) 1:500
rPAb rabbit polyclonal antibody, mMAb mouse monoclonal antibody
Absence of caveolin-1−/− alters PTEN and NHERF1 expression
Author's personal copy
Statistical analysis
Statistical analyses were completed using the Prism com-
puter program (Graph Pad Software, San Diego, CA); two-
tailed paired t-test was used for data analysis, a p value
o<0.05 was considered significant.
Results
Co-localization of Her-2/neu and β-catenin in Cav-1+/+ and
Cav-1−/− tumors driven by Her-2/neu expression
In a previous examination of these tumors, we reported that
Her-2/neu expression was not modified by the absence of Cav-
1 (Ciocca et al. 2012). We have now explored the levels of β-
catenin and the first notable observation was the co-localization
of this protein with Her-2/neu. Both proteins appeared on the
Fig. 1 Representative photographs of the MMTV-c-neu carcinomas
immunostained to reveal Her-2/neu and β-catenin. a Negative control
using an isotype matched antibody staining of a mammary tumor. Note
that in this study we did not have background cross-reaction problems
with the immune detection of mouse antigens even when one of the
antibodies (anti β-catenin) was of mouse origin (Table 1). b Positive
control for Her-2/neu in the membrane of the tumor cells. c Positive
control for β-catenin which appears at the membrane of the epithelial
cells in the skin of a mouse. d High-power micrograph to reveal Her-2/
neu in a tumor from a Cav-1+/+ transgenic mouse. e β-Catenin
immunostaining in a serial section from panel d. β-Catenin can be
seen at the cell membrane of the tumor cells. f High-power micrograph
reveals Her-2/neu in a tumor from a Cav-1−/− transgenic mouse and a
serial section (g) shows immunostaining for β-catenin in the Cav-1−/−
mouse tumor. β-catenin can be seen at the cell membrane of the tumor
cells. The images were captured with a Nikon Eclipse E200 micro-
scope (×10–60 objectives). The positive immunoreactivity appears as
brown deposits, and the slides were lightly counterstained with hema-
toxylin to reveal nuclei. Figure magnifications: a bar = 100 μm, b and
c bar = 70 μm, d–e bar = 25 μm, f–gbar = 35 μm
Table 2 Expression levels of the Her-2/neu, β-catenin, MTA1 and Akt
in tumors from Cav-1+/+ and Cav-1−/− mice (semiquantitative evalua-
tion completed on immunostained samples)
Molecule Scorea in Cav-1+/+ Score1 in Cav-1−/− p value
Her-2/neu 4.8 4.6 NS
β-Catenin 4.4 4.16 NS
MTA1 3.72 3.69 NS
p-Akt 2.8 2.37 NS
NS not significant
a The scoring system used is described in the “Materials and methods”
section
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surface of the tumor cells, and in the same tumor areas (Fig. 1).
The second observation was that, similar to Her-2/neu, the
absence of Cav-1 did not significantly change the levels of β-
catenin (Table 2). In addition, at a histological level, the tumor
cells did not display characteristics of an EMTwhen Cav-1 was
absent (Fig. 1 and the following figures).
The similar levels and localization of Her-2/neu and β-
catenin were maintained from the onset of cancer in early
hyperplastic lesions, (data not shown) to advanced stage can-
cer, when the cell clusters were invading the blood vessels
(Fig. 2a, b).
MTA1, PTEN, p-Akt and NHERF1 expression in the Cav-1 +/+
and Cav-1−/− tumors driven by Her-2/neu expression
MTA1 is induced in human breast cancer cells expressing
Her-2/neu (Khaleque et al. 2008). Similarly, in mice MTA1
was present in the nuclei of numerous tumor cells (Fig. 3).
However, the absence of Cav-1 did not significantly alter
MTA1 expression (Table 2).
In a previous study, we showed that Hsp27 levels were
significantly lower in the Cav-1−/− tumors (Ciocca et al.
2012), and recently we have shown that Hsp27 down-
regulation increased the expression of PTEN in human MCF-
7 breast cancer cells (Cayado-Gutiérrez et al. 2012). In the
present study, PTEN was detected with two different anti-
bodies (Fig. 4a) and significant changes were found in
tumors arising from Cav-1 null mice (Fig. 4b). The two
different antibodies revealed significantly higher PTEN ex-
pression in the tumors grown in the absence of Cav-1, with
the protein was mainly localized in the nuclei. “Normal”
mammary glands at the periphery of the Cav1 null tumors
also showed higher PTEN levels in the nuclei of the
luminal epithelial cells.
We also studied two proteins linked functionally to
PTEN: p-Akt and NHERF1. P-Akt levels were relatively
low in the Her2/neu tumors (Table 2, Fig. 5a). The levels of
this protein did not change significantly in either the tumor
or in the stroma, when Cav-1 was absent. In contrast,
NHERF1 expression levels were increased in the tumors
arising in Cav-1 KO mice (Fig. 5b). The protein was present
mainly in the nuclei of the tumor cells.
Discussion
In a previous study using the same transgenic/KO animal
model, we reported that the disruption of the Cav-1 gene
Fig. 2 Her-2/neu and β-catenin in a mouse carcinoma from an
MMTV-c-neu mouse (Cav-1−/−). a Large cell cluster showing Her-2/
neu expression at the periphery of the tumor nests invading a blood
vessel. b In this serial section, the cell cluster shows β-catenin at the
cell membrane of the tumor cells. The positive immunoreactivity
appears as brown deposits, and the slides were lightly counterstained
with hematoxylin to reveal nuclei. Figure magnifications: a–b
bar = 20 μm
Fig. 3 MTA1 in Her-2/neu mammary tumors. a Negative control
using an isotype matched antibody staining of a mammary tumor. b
MTA1 appears in the nuclei of numerous tumor cells in a Cav-1+/+
tumor. c Similar MTA1 levels can be seen in tumors from Cav-1 null
mice. The positive immunoreactivity appears as brown deposits, and
the slides were lightly counterstained with hematoxylin to reveal
nuclei. Figure magnifications: a–c bar = 25 μm
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caused alterations in the stress proteins Hsp27, Hsp70 and
gp96, as well as in tumor development (Ciocca et al. 2012).
We have now advanced these studies by examining other
stress-related proteins. The dual functions of Cav-1 on both
the cancer epithelium and the cancer stroma are well docu-
mented, and there is evidence indicating that Cav-1 deple-
tion causes mislocalization of β-catenin and E-cadherin.
These changes are characteristic of EMT in epithelial mam-
mary acini (Mercier and Lisanti 2011). In our study, not only
was there no mislocalization of β-catenin in the Cav-1 KO
mice, there were also no histological changes indicative of
EMT, and β-catenin remained co-expressed with Her-2/neu
on the surface of the tumor cells. In other transgenic mouse
models (MMTV-Wnt-1 and MMTV-c-Neu), an indispens-
able interaction between β-catenin and Her-2/neu hetero-
dimers at the cell membrane has been reported, indicating
that the interactions between the two molecules is an impor-
tant signaling event for human breast cancer progression
(Schroeder et al. 2002). In contrast, using a similar mouse
tumor model (MMTV/neu) but where the mice expressed a
mammary-targeted, mutationally activated HER2/neu allele,
cytoplasmic β-catenin was detected in the HER2/neu-in-
duced mouse mammary tumors (Khalil et al. 2012). In
addition, the same authors reported in breast cancer patients
a correlation between Her-2/neu expression and nucleo/cy-
toplasmic β-catenin in lymph node-positive carcinomas.
Moreover, it is relevant to report here that in a human
hypopharyngeal cancer cell line, EGF treatment induced
an increased physical interaction between EGFR/β-catenin/-
caveolin-1 and between E-cadherin/β-catenin/caveolin-1
(Masuelli et al. 2012). These authors also found in human
head and neck squamous cell cancer biopsy samples that
Cav-1 over-expression appeared associated with simulta-
neous abnormal expression of the E-cadherin/α-β-catenin
complex and with multiple ErbB receptors resulting in a
more aggressive phenotype.
Several molecules are influenced when Her-2/neu is activat-
ed. Two of them, MTA1 and heat shock factor 1, are strongly
Fig. 4 PTEN in MCF-7 human breast cancer cell line (a) and in mouse
tumors (b). a Two different MW bands were detected using the anti-
bodies, one at 76 kDa (antibody PTENa) and the other at 55 kDa
(antibody PTENb) (see “Materials and methods” section and Cayado-
Gutiérrez et al. 2012). b (a) negative control using an isotype matched
antibody staining of a mammary tumor. (b and c) Note the increased
expression of PTEN in the Cav-1−/− tumor using the anti PTENa
antibody (graph, p <0.05). (d) Negative control using an isotype
matched antibody staining of a mammary tumor. (e and f) Note again
the increased expression of PTEN in the Cav-1−/− tumor using the anti
PTENb antibody (graph, p<0.05). Relatively “normal” mammary
gland also showed more PTEN expression in the Cav-1 KO mouse
(g and h, using the anti-PTENb antibody). The positive immunoreac-
tivity appears as brown deposits, and the slides were lightly counter-
stained with hematoxylin to reveal nuclei. Figure magnifications, a–f:
bar = 70 μm, g and h: bar = 50 μm
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induced and form complexes (both together and with other
proteins) that participate in the repression of estrogen-
dependent transcription (Khaleque et al. 2008). In the mouse
model used in this study, the tumor cells did not express estrogen
receptor alpha or beta and although heat shock factor 1 was
present, the levels were not altered by the absence of Cav-1
(Ciocca et al. 2012). Likewise, the tumors expressedMTA1, but
once again the levels were not affected by the Cav-1 status.
PTEN helps to maintain the balance of tyrosine phos-
phorylation of cellular proteins implicated in normal and
pathological signaling pathways. Most protein tyrosine
phosphatases, including PTEN, contain at least one Cav-1-
binding motif that results in the formation of molecular
complexes (Caselli et al. 2002). Therefore, at least on the
cell surface and in cytoplasmic membranes, Cav-1 is asso-
ciated with PTEN (Caselli et al. 2002). In our study, Cav-1
was not detected by IHC in the cancer cells from the Cav-1
wild type tumors even though the stroma was positive for
Cav-1 (Ciocca et al. 2012). However, PTEN was present in
both the Cav-1 wild type and null tumors. Therefore, although
Cav-1 interacts with PTEN, the tumor cells can express PTEN
in the absence of Cav-1 and we found that the absence of Cav-
1 in the stroma significantly induced the tumor cells to express
more PTEN. The tumors also had lower Hsp27 levels (Ciocca
et al. 2012). These findings support our recent study where we
showed the down regulation of Hsp27 to induce over-
expression of PTEN (Cayado-Gutiérrez et al. 2012).
The increase in PTEN was seen mainly in the nuclei of the
epithelial cancer cells. Nuclear PTEN has been associated
with regulation of the expression of many genes, and although
the mechanism of this regulation remains unclear, it has been
postulated that PTENmay have a non-phosphatase function in
the nucleus (Moncalero et al. 2011). In the present study we
did not find significant changes in p-Akt levels when Cav-1
was absent, which validates a non-phosphatase role of PTEN.
In a previous study, an increase in PTENwas accompanied by
a decrease in p-Akt (Cayado-Gutiérrez et al. 2012). Aldred et
al. (2003) reported that nuclear PTEN is found predominantly
in normal thyroid glands but not in thyroid carcinomas, where
the PTEN levels are low and located in the cytoplasm. Several
reports indicate that more aggressive cancers are linked to
the absence of nuclear PTEN (Whiteman et al. 2002; Zhou
et al. 2002; Tsutsui et al. 2005; Fridberg et al. 2007). Of
interest in our study is that the group of animals with
mammary adenocarcinomas grown in Cav-1 null mice
showed a trend towards a lower incidence of visible lung
metastases than the tumors grown in Cav-1+/+ mice (20 %
vs. 28 %; Sloan et al. 2009). In contrast, the absence of
Cav-1 reduced the amount of apoptosis and caused an
earlier onset of mammary tumors, while in breast cancer
patients the absence of Cav-1 in the stroma has been related
with a more aggressive phenotype. Therefore, future stud-
ies are required to clarify the apparent discrepancies be-
tween the transgenic mouse model and the cancer patients.
Fig. 5 Representative photographs of the MMTV-c-neu transgenic car-
cinomas immunostained to reveal p-Akt and NHERF1. a Western blot
showing that the anti p-Akt antibody detected a 70-kDaMWband (MCF-
7 cells); the same paper was incubated with anti-tubulin (lower band).
There is a relatively low p-Akt expression in the tumors (a and b). In one
of the tumors grown in a Cav-1−/− mouse (b), cells at the periphery of a
tumor nest shows more p-Akt, but this did not change the overall scores
(Table 2). bWestern blot is not shown here because the specificity of the
antibody was demonstrated in a previous study (Cuello-Carrión et al.
2010). (a) Positive control using colon, the immunoreaction can be seen
at the cell surface and in some nuclei. Note the increased expression of
NHERF1 in the Cav-1−/− tumors, mainly in the nuclei (b and c, p<0.05).
The positive immunoreactivity appears as brown deposits, and the slides
were lightly counterstained with hematoxylin to reveal nuclei. Figure
magnifications, bar = 25 μm
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In this study, as was the case with PTEN, NHERF1 was
also elevated in tumor cells from Cav-1 null mice, and both
proteins appeared mainly in the nucleus. In the cytoplasm,
NHERF proteins recruit PTEN to PDGFR to restrict the
activation of the PI3K (Takahashi et al. 2006). NHERF1 also
complexes directly (through the PDZ2 domain) with β-
catenin, and this association is important in maintaining β-
catenin localization at the cell surface (Kreimann et al. 2007).
Our study revealed that these three proteins can follow differ-
ent cellular localization routes, since even when PTEN and
NHERF1 are in the nucleus, β-catenin can still be on the cell
surface. The question beckons, what is NHERF1 doing in the
nucleus? It seems that NHERF1 can stabilize β-catenin/TCF-
1 complexes, which causes β-catenin to bind to dominant
negative TCF-1. This in turn results in enhanced Wnt/β-
catenin signaling events that influence the transcription of
downstream oncogenes (c-Myc and cyclin D1) (Lin et al.
2012). These authors also reported that nuclear NHERF1 is
related to poor clinical outcome in colon cancer. In our study,
tumor onset was more rapid in mice lacking Cav-1 and these
animals had a shorter overall survival (Sloan et al. 2009).
Additional experiments should be completed to clarify the
role(s) of nuclear NHERF1 (independent of β-catenin).
Taken together, the data obtained from the MMTV-neu
model are consistent with a role for Cav-1 in stromal cells in
breast cancer by modulating the expression and localization
of proteins implicated in tumor progression.
Acknowledgments This work was supported by the National Re-
search Council of Argentina (CONICET) (PIP 2428 to DRC), the
Agencia Nacional de Promoción Científica y Tecnológica of Argentina
(PICT 1047, 2007, préstamo BID, DRC), the Argentina Foundation for
Cancer Research (DRC) and by grants from the Susan G. Komen for
the Cure (BCTR0403075 to RLA) and from the Cancer Council
Victoria (RLA) and by a fellowship from the National Breast Cancer
Foundation of Australia (RLA). This work is part of the thesis (NCG)
for PROBIOL, UNCuyo, Mendoza, Argentina.
References
Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O,
Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C
(2003) Caveolin-1 and caveolin-2, together with three bone mor-
phogenetic protein-related genes, may encode novel tumor suppres-
sors down-regulated in sporadic follicular thyroid carcinogenesis.
Cancer Res 63:2864–2871
Caselli A, Mazzinghi B, Camici G, Manao G, Ramponi G (2002) Some
protein tyrosine phosphatases target in part to lipid rafts and interact
with caveolin-1. Biochem Biophys Res Commun 296:692–697
Cayado-Gutiérrez N, Moncalero VL, Rosales EM, Berón W,
Salvatierra EE, Alvarez-Olmedo D, Radrizzani M, Ciocca DR
(2012) Down-regulation of Hsp27 (HSPB1) in MCF-7 human
breast cancer cells induces up-regulation of PTEN. Cell Stress
and Chaperones. doi:10.1007/s12192-012-0367-x
Ciocca DR, Gago FE, Fanelli MA, Calderwood SA (2006) Co-
expression of steroid hormone receptors (estrogen receptor α
and/or progesterone receptors) and Her2/neu: clinical implica-
tions. J Steroid Biochem Mol Biol 102:32–40
Ciocca DR, Cuello-Carrión FD, Natoli AL, Restall C, Anderson RL
(2012) Absence of caveolin-1 alters heat shock protein expression
in spontaneous mammary tumors driven by Her-2/neu expression.
Histochem Cell Biol 137:187–194
Cuello-Carrión FD, Troncoso M, Guiñazu E, Valdez SR, Fanelli MA,
Ciocca DR, Kreimann EL (2010) Estrogens regulate the expres-
sion of NHERF1 in normal colon during the reproductive cycle of
Wistar rats. Histochem Cell Biol 134:623–630
Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B,
Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H
(2001) Kurzchalia TV (2001) Loss of caveolae, vascular dysfunc-
tion, and pulmonary defects in caveolin-1 gene-disrupted mice.
Science 293:2449–2452
Fanelli MA, Montt-Guevara M, Diblasi AM, Gago FE, Tello O,
Cuello-Carrión FD, Callegary E, Bausero MA, Ciocca DR
(2008) P-cadherin and β-catenin are useful prognostic markers
in breast cancer patients; β-catenin interacts with heat shock
protein Hsp27. Cell Stress Chaperones 13:207–220
Fiandalo MV, Kyprianou N (2012) Caspase control: protagonists of
cancer cell apoptosis. Exp Oncol 34:165–175
Fridberg M, Servin A, Anagnostaki L, Linderoth J, Berglund M et al
(2007) Protein expression and cellular localization in two prog-
nostic subgroups of diffuse large B-cell lymphoma: higher ex-
pression of ZAP70 and PKC-beta II in the non-germinal center
group and poor survival in patients deficient in nuclear PTEN.
Leuk Lymphoma 48:2221–2232
Fukunaga K, Shioda N (2009) Pathophysiological relevance of fork-
head transcription factors in brain ischemia. Adv Exp Med Biol
665:130–142
Gago FE, Tello OM, Diblasi AM, Ciocca DR (1998) Integration of
estrogen and progesterone receptors with pathological and molec-
ular prognostic factors in breast cancer patients. J Steroid
Biochem Mol Biol 67:431–437
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ
(1992) Expression of the neu protooncogene in the mammary
epithelium of transgenic mice induces metastatic disease. Proc
Natl Acad Sci USA 89:10578–10582
Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z,
McCubrey JA, Travali S, Libra M (2012) Gene alterations in the
PI3K/PTEN/AKT pathway as a mechanism of drug-resistance
(review). Int J Oncol 40:639–644
Khaleque A, Bharti A, Gong J, Ciocca D, Stati A, Fanelli M, Calderwood
SK (2008) Heat shock factor 1 represses estrogen dependent tran-
scription through association with MTA1. Oncogene 27:1886–1893
Khalil S, Tan GA, Giri DD, Zhou XK, Howe LR (2012) Activation
status of Wnt/ß-catenin signaling in normal and neoplastic breast
tissues: relationship to HER2/neu expression in human and
mouse. PLoS One 7(3):e33421
Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford
EA, Chetham ME, Chen B, Hightower LE (2009) Guidelines for
the nomenclature of the human heat shock proteins. Cell Stress
Chaperones 14:105–111
Kreimann EL, Morales FC, de Orbeta-Cruz J, Takahashi Y, Adams H,
Liu TJ, McCrea PD, Georgescu MM (2007) Cortical stabilization
of beta-catenin contributes to NHERF1/EBP50 tumor suppressor
function. Oncogene 26:5290–5299
Lin YY, Hsu YH, Huang HY, Shann YJ, Huang CY, Wei SC, Chen CL,
Jou TS (2012) Aberrant nuclear localization of EBP50 promotes
colorectal carcinogenesis in xenotransplanted mice by modulating
TCF-1 and β-catenin interactions. J Clin Invest 122:1881–
1894
F.D. Cuello-Carrión et al.
Author's personal copy
Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di
Gennaro E, Losito S, Sale P, Longo F, Ionna F, Lista F, Muraro R,
Modesti A, Bei R (2012) Caveolin-1 overexpression is associated
with simultaneous abnormal expression of the E-cadherin/α-β
catenins complex and multiple ErbB receptors and with lymph
nodes metastasis in head and neck squamous cell carcinomas. J
Cell Physiol 227:3344–3353
Mercier I, Lisanti MP (2011) Caveolin-1 and breast cancer: a new clinical
perspective. In: Caveolins and Caveolae: Roles in Signaling and
Disease Mechanisms, edited by Jean-François Jasmin, Philippe G.
Frank and Michael P. Lisanti. Landes Bioscience and Springer
Science+Business Media, pp. 1–12
Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G,
Georgescu MM (2012) PTEN, NHERF1 and PHLPP form a
tumor suppressor network that is disabled in glioblastoma.
Oncogene 31:1264–1274
Moncalero VL, Costanzo RV, Perandones C, Radrizzani M (2011)
Different conformations of phosphatase and tensin homolog, de-
leted on chromosome 10 (PTEN) protein within the nucleus and
cytoplasm of neurons. PLoS One 6(4):e18857
Pan Y, Wang L, Dai JL (2006) Suppression of breast cancer cell growth
by Na+/H+ exchanger regulatory factor 1 (NHERF1). Breast
Cancer Res 8:R63
Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro
MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-
Outschoorn UE, Sotgia F, Lisanti MP (2010) Loss of stromal
caveolin-1 leads to oxidative stress, mimics hypoxia and drives
inflammation in the tumor microenvironment, conferring the “re-
verse Warburg effect”: a transcriptional informatics analysis with
validation. Cell Cycle 9:2201–2219
Perandones C, Costanzo RV, Kowaljow V, Pivetta OH, Carminatti H,
Radrizzani M (2004) Correlation between synaptogenesis and the
PTEN phosphatase expression in dendrites during postnatal brain
development. Brain Res Mol Brain Res 128:8–19
Schroeder JA, Adriance MC, McConnell EJ, Thompson MC,
Pockaj B, Gendler SJ (2002) ErbB-beta-catenin complexes
are associated with human infiltrating ductal breast and
murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-
c-Neu transgenic carcinomas. J Biol Chem 277:22692–
22698
Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S (2003)
EBP50, a beta-catenin-associating protein, enhances Wnt signaling
and is over-expressed in hepatocellular carcinoma. Hepatology
38:178–186
Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA,
Fanelli MA, Cuello-Carrión FD, Gago FE, Anderson RL (2009)
Stromal cell expression of caveolin-1 predicts outcome in breast
cancer. Am J Pathol 174:2035–2043
Takahashi Y, Morales FC, Kreimann EL, Georgescu MM (2006) PTEN
tumor suppressor associates with NHERF proteins to attenuate
PDGF receptor signaling. EMBO J 25:910–920
Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M
(2005) Reduced expression of PTEN protein and its prognostic
implications in invasive ductal carcinoma of the breast. Oncology
68:398–404
Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK et al
(2002) Nuclear PTEN expression and clinicopathologic features
in a population-based series of primary cutaneous melanoma. Int J
Cancer 99:63–67
Yang L, Wang Y, Chen P, Hu J, Xiong Y, Feng D, Liu H, Zhang H,
Yang H, He J (2011) Na(+)/H(+) exchanger regulatory factor 1
(NHERF1) is required for the estradiol-dependent increase of
phosphatase and tensin homolog (PTEN) protein expression.
Endocrinology 152:4537–4549
Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P et al
(2002) PTEN mutational spectra, expression levels, and subcellu-
lar localization in microsatellite stable and unstable colorectal
cancers. Am J Pathol 161:439–447
Absence of caveolin-1−/− alters PTEN and NHERF1 expression
Author's personal copy
